POS1440 HEMATOLOGICAL MALIGNANCIES AND ANTI-TNF IN INFLAMMATORY ARTHRITIS: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY

4.6

(667)

$ 11.50 In stock

Product Description

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor, Arthritis Research & Therapy

U. Kalyoncu's research works Hacettepe University, Ankara and other places

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers - eBioMedicine

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor, Arthritis Research & Therapy

Ertugrul Cagri BOLEK, Fellow, M.D. M.Sc., Hacettepe University, Ankara, Division of Rheumatology, Department of Internal Medicine

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis

PDF) Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Gözde YARDIMCI, Doctor of Medicine, Hacettepe University, Ankara, Department of Rheumatology

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD

PDF) Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial - The Lancet